TY - JOUR T1 - Tolerability of Molecular-targeted Agents for Hepatocellular Carcinoma Treatment in Haemophiliacs JF - Anticancer Research JO - Anticancer Res SP - 2569 LP - 2573 DO - 10.21873/anticanres.15035 VL - 41 IS - 5 AU - TAKAFUMI YAMAMOTO AU - NORIHIRO IMAI AU - KENTA YAMAMOTO AU - TAKANORI ITO AU - YOJI ISHIZU AU - TAKASHI HONDA AU - SHUICHI OKAMOTO AU - TAKESHI KANEMATSU AU - NOBUAKI SUZUKI AU - TADASHI MATSUSHITA AU - MASATOSHI ISHIGAMI AU - MITSUHIRO FUJISHIRO Y1 - 2021/05/01 UR - http://ar.iiarjournals.org/content/41/5/2569.abstract N2 - Background: Hepatocellular carcinoma (HCC) is considered a leading cause of death in patients with haemophilia. Recent advances in the treatment of unresectable HCC with molecular-targeted agents (MTAs) have led to better clinical outcomes. However, the tolerability of MTAs by haemophilic patients with HCC remains unclear. Aim: This study aimed to compare the tolerability of MTAs in such patients. Patients and Methods: From January 2011 to October 2020, five haemophilic patients with HCC were treated with MTAs. Adverse events were assessed in comparison with 265 non-haemophilic patients with HCC. Results: The prevalence of hand–foot skin reaction was not higher in the haemophiliacs than in the non-haemophiliacs, whereas the rate of haemorrhagic events was higher in the haemophiliacs (6.0% versus 40.0%, p=0.037). Conclusion: Haemophiliacs tolerate long-term MTA use, without the occurrence of life-threatening complications. However, careful observation and prevention are needed for MTA-related gastrointestinal bleeding in haemophiliacs. ER -